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Background: Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic
hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed
treatment comparison (MTC) meta-analysis to compare clinical trials examining the use of oral antifungals for
prophylaxis in alloHCT recipients, with the goal of informing medical decision-making.
Methods: Randomized controlled trials (RCTs) of fluconazole, itraconazole, posaconazole, and voriconazole for
primary antifungal prophylaxis were identified through a systematic literature review. Outcomes of interest (incidence
of IFI/invasive aspergillosis/invasive candidiasis, all-cause mortality, and use of other antifungals) were extracted from
eligible RCTs and incorporated into a Bayesian hierarchical random-effects MTC.
Results: Five eligible RCTs, randomizing 2147 patients in total, were included. Relative to fluconazole, prophylaxis with
itraconazole (odds ratio [OR]: 0.52; interquartile range [IQR]: 0.35–0.76), posaconazole (OR: 0.56; IQR: 0.32–0.99), and
voriconazole (OR: 0.46; IQR: 0.28–0.73) reduced incidence of overall proven/probable IFI. Posaconazole (OR: 0.31;
IQR: 0.17–0.58) and voriconazole (OR: 0.33; IQR: 0.17–0.58) prophylaxis reduced proven/probable invasive aspergillosis
more than itraconazole (OR: 0.68; IQR: 0.42–1.12). All-cause mortality was similar across all mould-active agents.
Conclusion: As expected, mould-active azoles prevented IFIs, particularly invasive aspergillosis, more effectively than
fluconazole in alloHCT recipients. The paucity of comparative efficacy data suggests that other factors such as
long-term tolerability, availability of intravenous formulations, local IFI epidemiology, and drug costs may need to
form the basis for selection among the mould-active azoles.
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Invasive fungal infections (IFI) are a significant cause
of morbidity and mortality in allogeneic hematopoietic
cell transplant (alloHCT) recipients, with invasive mould
infections due to Aspergillus spp. (invasive aspergillosis,
IA) being most prevalent [1-4]. Early treatment strategies
and antifungal prophylaxis are options for mitigating
the impact of IFI in this population [5-7]. Although a* Correspondence: EJBow@cancercare.mb.ca
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gal prophylaxis reduced all-cause mortality, IFI-related
mortality, and IFI incidence in alloHCT recipients [8], a
more recent systematic review failed to demonstrate
consistent treatment effects for these outcomes using
direct and indirect comparisons [9]. For antifungal
prophylaxis, particularly in the long-term outpatient
setting, oral antifungals have the potential to be conveni-
ent and cost-effective [10,11]. However, the optimum oral
agent for antifungal prophylaxis in alloHCT recipients
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systemically active oral antifungal, the principal choices
are fluconazole, which lacks anti-mould activity, and
the mould-active agents itraconazole, posaconazole, and
voriconazole. To our knowledge no single head-to-head
randomized clinical trial (RCT) has directly compared
more than 2 of these options in alloHCT recipients. The
paucity of such studies impedes the use of traditional
pairwise meta-analysis to inform the clinical decision-
making process.
Network meta-analysis, can synthesize head-to-head
comparisons of interventions not directly compared in
clinical trials, as long as these interventions share one or
more common comparators in a network of evidence.
Furthermore, mixed treatment comparison (MTC) net-
work meta-analyses allow for the combination of both
direct and indirect evidence [12,13], and have been
successfully employed to address similar questions in
numerous clinical areas, including cardiovascular dis-
ease, osteoporosis, and bacterial infections [14-18], as
well as for comparisons of different agents and strategies
for antifungal treatment [19,20]. To extend a previously
published traditional meta-analysis of antifungal prophy-
laxis [8], we conducted a systematic literature review
and MTC of RCTs evaluating fluconazole, itraconazole,
posaconazole, and voriconazole as primary antifungal
prophylaxis in alloHCT recipients, including recently
published trials. Our objective was to compare the effi-
cacy of these agents for the prevention of documented
IFI in alloHCT recipients based on several key out-




We conducted a systematic literature review in 2014 to
identify all relevant RCTs evaluating fluconazole, itra-
conazole, posaconazole, and voriconazole for primary
oral antifungal prophylaxis in alloHCT recipients post-
transplant. The search process and full inclusion/
exclusion criteria are shown in Figure 1. The risk of
bias across studies could not be assessed, since mul-
tiple studies assessing the same treatment effect were
not available.
Only RCTs meeting the search criteria were included
in the MTC network analysis of fluconazole, itracona-
zole, posaconazole, and voriconazole if they included a
comparator common to multiple RCTs. For example,
the hypothetical common comparator “C” can indirectly
link comparators of interest “A” and “B” in Trial 1 com-
paring interventions “A” versus “C” and Trial 2 compar-
ing “B” versus “C”. However, Trial 3 comparing “B”
versus “D” would not be included in the hypothetical
“A” versus “B” network since comparator “D” is neithera comparator of interest nor a common comparator that
can indirectly inform an “A” versus “B” comparison.
Outcomes evaluated
The main outcome of interest was the incidence of
proven/probable IFI using the consensus criteria described
by Ascioglu et al. [21]. Other outcomes were all-cause
mortality, proven/probable IA, proven invasive candidiasis
(IC), and administration of other licensed antifungal ther-
apy (OLAT; defined as any systemic antifungal other than
randomized study drug, including a temporary switch to
an intravenous agent in patients not tolerating oral
prophylaxis). The cumulative proportions of patients for
each of these outcomes at 180 days post-transplant (or the
closest available time point) were extracted from each
RCT. Data extraction was performed in duplicate by 2 of
the authors (LC, AJS) and the extracted data were inde-
pendently reviewed by 2 additional authors (EJB, SS).
Quantitative data synthesis
We used Bayesian hierarchical random-effects MTCs,
estimated with Markov Chain Monte Carlo methods
(WinBUGS v.1.4.3), to estimate posterior distributions
for the comparative effectiveness of the interventions for
each of the extracted outcomes [22]. These posterior
distributions estimate the probability, given available evi-
dence and a specified statistical model, that the com-
parative effectiveness takes on a particular value or lies
within a specified range of values. For example, the
probability is 75% (3:1 odds) that the true value of an
odds ratio lies below the upper bound of the posterior
interquartile range. A central 95% credible interval is
comparable to a classical 95% confidence interval but,
unlike the classical confidence interval, can be inter-
preted as having 95% probability of containing the true
value. The probability is 97.5% (39:1 odds) that the true
value of an odds ratio lies below the upper bound of the
central 95% credible interval.
Posterior probabilities can also be used to estimate the
probability that one treatment is more effective than
another for each outcome, an advantage for informing
decision-makers in cases where traditional thresholds of
statistical significance (ie, 95%) cannot be achieved using
standard methods [14]. In this MTC, we estimated the
probability that each treatment resulted in a lower inci-
dence than fluconazole for the respective outcome and
the probability for each treatment to have the lowest in-
cidence of all treatments (including fluconazole) for the
respective outcome to help identify the most effective
antifungal.
Model selection
We used a conservative unconstrained baseline approach
to account for potential between-trial heterogeneity in
Figure 1 Flow chart of the systematic literature review process and inclusion/exclusion criteria.
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[14,18,23]. Our random effect specification for the treat-
ment effect parameters assumed that the included trials
are similar enough, both clinically and methodologically,
that the estimated differences in treatment efficacy (in this
case all-cause mortality, IFI risk, and OLAT use for each
comparator relative to fluconazole) are “exchangeable” or
similar across trials [13]. While we expected baseline in-
fection risks to differ among trials according to timeframe
and clinical context, we had no a priori expectations for
systematic differences in relative risks by treatment.
Bayesian meta-analysis allows for uncertainty in the
amount of heterogeneity of treatment effects between
studies. We followed standard approaches for assigning
a non-informative prior to the heterogeneity parameter.
However, in cases such as our analysis, where MTCs
include a relatively small number of studies, results can
be sensitive to the choice of prior distribution for the
parameter estimating the degree of heterogeneity [24].
Furthermore, the use of a non-informative prior when
the number of included studies is small can fail to rule
out unrealistically large degrees of heterogeneity. There-
fore, we conducted a post-hoc sensitivity analysis based
on previously published empirical Bayesian methods,
which used variation in observed pairwise treatment
effectiveness estimates to provide a modestly informative
prior for heterogeneity [24,25]. Full details of the statis-
tical analysis and model code are provided in the online
Additional file 1.
Results
Summary of included studies
The systematic literature search identified 5 published
RCTs that met predefined criteria for inclusion into
the MTC [10,26-29]. Our literature search identified 6
additional RCTs that were not able to directly or indir-
ectly inform a comparison of fluconazole, itraconazole,
posaconazole, and voriconazole [30-35]. A flow chart
of search results and a summary of each trial’s charac-
teristics and patient populations are shown in the online
Additional file 1. The 5 head-to-head studies [10,26-29]
constituting the evidence network (Figure 2) for the MTC
randomized a total of 2147 patients, with individual study
sample sizes ranging from 140–600 patients. Four studies
were multicentre trials, 3 studies had an open-label design,
and 2 had a double-blind design. Fluconazole (with a total
of 813 randomized patients) was a comparator in 4 RCTs,
itraconazole (n = 485) was a comparator in 3, voriconazole
(n = 548) in 2, and posaconazole (n = 301) was a compara-
tor in a single trial. The data extracted from these studies
for each outcome are shown in Table 1. The overall esti-
mates of heterogeneity were large, particularly in the
main analysis using a non-informative prior (see online
Additional file 1).MTC results
Based on the MTC estimates, voriconazole was the
agent most likely to reduce incidence of overall proven/
probable IFI at 180 days post-transplant relative to flu-
conazole, closely followed by itraconazole and posacona-
zole; this conclusion was reflected in the posterior
probability of having a lower IFI risk than fluconazole
and the posterior probability of having the lowest IFI
risk among the 4 agents, both of which were most
favourable with voriconazole (Table 2). However, in the
base-case analysis, none of the risk differences in this
outcome, nor any of the other outcomes (below), reached
statistical significance at the standard 95% level – ie, all
posterior probabilities of differences in outcomes were
found to be less than 0.95.
MTC estimates suggested that voriconazole and posa-
conazole were associated with the greatest reduction in
probability of proven/probable IA by day 180 post-
transplant relative to fluconazole, followed by itracona-
zole (Table 2). Voriconazole prophylaxis was more likely
to yield a lower risk of proven/probable IA by day 180
relative to fluconazole (probability of 87%) than either
posaconazole (83%) or itraconazole (71%). Posaconazole
had a higher posterior probability of having the lowest
IA risk by day 180 post-transplant (47%) than voricona-
zole (41%); the respective probability was only 9% for
itraconazole and 2% for fluconazole.
Itraconazole had the most favourable estimated treat-
ment effect on the prevention of proven IC at 180 days
post-transplant relative to fluconazole, while posaconazole
and voriconazole appeared to have a similar treatment
effect to fluconazole (Table 2). In terms of avoiding the
need to use OLAT, voriconazole had the most favourable
estimated treatment effect, based on the observation that
its posterior probability of having the lowest incidence of
OLAT use (ie, 49%) was about 2–5 times higher than that
for the other 3 agents; for this outcome, the probability
that voriconazole was better than fluconazole was 73%, ie,
about 20% higher than for itraconazole and 30% higher
than for posaconazole (Table 2). There were no note-
worthy differences between any of the azoles in all-cause
mortality (Table 2).
The post-hoc sensitivity analysis using an empirical
Bayesian prior for the heterogeneity parameter (see
Methods section for details), yielded estimated treat-
ment effects comparable to the base case (Table 3).
However, credible intervals in this additional analysis
were considerably less wide than in the base case; to
illustrate this point, estimated posterior credible inter-
vals (on the log-odds scale) for IFI overall and IA from
both analyses are depicted in Figure 3A and B, res-
pectively. Some of the notable differences in posterior
probabilities observed in the base-case analysis became
even more pronounced in the sensitivity analysis: for
Figure 2 Evidence network of randomized controlled trials (RCTs) included into the mixed treatment comparison (MTC).
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zole being better than fluconazole for prevention of IFI
and the probability of posaconazole and voriconazole
being better than fluconazole for prevention of IA were
now found to be ≥95% and thus reached traditional
thresholds of statistical significance. Results for all
outcomes were very similar in a sensitivity analysis
that excluded the single posaconazole RCT (see online
Additional file 1), and was therefore limited to flucona-
zole, itraconazole, and voriconazole.
Discussion
Transplant physicians are frequently faced with the difficult






Fluconazole 28/67 (42%) 17/67 (25%)
Itraconazole 32/71 (45%) 6/71 (8%)
Marr 2004 [26]
Fluconazole 44/148 (30%) 25/148 (17%)
Itraconazole 55/151 (36%) 19/151 (13%)a
Ullmann 2007 [27]
Fluconazole 59/299 (20%) 27/299 (9%)
Posaconazole 58/301 (19%) 16/301 (5%)
Wingard 2010 [28]
Fluconazole 59/295 (20%) 24/295 (8%)
Voriconazole 57/305 (19%) 14/305 (5%)
Marks 2011 [10]
Itraconazole 44/241 (18%) 5/241 (2%)
Voriconazole 40/224 (18%) 3/224 (1%)
IFI, invasive fungal infections; IA, invasive aspergillosis; IC, invasive candidiasis; OLAT
aOne patient developed both proven IC and probable IA, which was counted as a soption for oral antifungal prophylaxis in alloHCT reci-
pients. In the absence of a large, multi-arm RCT com-
paring all systemically active oral antifungals, network
meta-analyses can provide relevant information to help
guide health intervention decision-making; this meth-
odology is increasingly utilized for similar purposes
across therapeutic areas [12,36].
Bayesian statistical inference differs from classical
statistics in that it provides probability distributions
for treatment effects, expressed as posterior credible
intervals (rather than confidence intervals) [37]. One
advantage of using Bayesian credible intervals is that
they can be more intuitively interpreted in terms of the







8/67 (12%) 8/67 (12%) Not reported
3/71 (4%) 2/71 (3%) Not reported
20/148 (14%) 5/148 (3%) 25/148 (17%)
16/151 (11%) 4/151 (3%) 19/151 (13%)
21/299 (7%) 4/299 (1%) 29/288 (10%)
7/301 (2%) 4/301 (1%) 31/291 (11%)
17/295 (6%) 5/295 (2%) 89/295 (30%)
9/305 (3%) 3/305 (1%) 73/305 (24%)
5/241(2%) 0/241 (0%) 101/241 (42%)
1/224 (0.4%) 2/224 (1%) 67/224 (30%)
, other licensed antifungal therapy.
ingle IFI instead of 2 separate IFIs.
Table 2 Estimated treatment effect for each outcome relative to fluconazole (base case analysis using a non-informed
prior)
Comparator Median posterior odds-ratio relative
to fluconazole (interquartile range)a
Posterior probability of having
lower incidence than fluconazole
Posterior probability of having the
lowest incidence of all treatments
Proven/probable IFI at 180 days
Fluconazole – – 2%
Itraconazole 0.52 (0.35–0.76) 84% 27%
Posaconazole 0.56 (0.32–0.99) 75% 32%
Voriconazole 0.46 (0.28–0.73) 84% 39%
Proven/probable IA at 180 days
Fluconazole – – 2%
Itraconazole 0.68 (0.42–1.12) 71% 9%
Posaconazole 0.31 (0.15–0.63) 83% 47%
Voriconazole 0.33 (0.17–0.58) 87% 41%
Proven IC at 180 days
Fluconazole – – 5%
Itraconazole 0.28 (0.11– 0.60) 85% 59%
Posaconazole 0.98 (0.28–3.45) 51% 23%
Voriconazole 1.19 (0.43–4.19) 46% 13%
All-cause mortality
Fluconazole – – 20%
Itraconazole 1.18 (0.96–1.44) 29% 11%
Posaconazole 0.98 (0.74–1.27) 53% 40%
Voriconazole 1.02 (0.82–1.26) 48% 29%
OLAT use at 180 days
Fluconazole – – 10%
Itraconazole 0.91 (0.49–1.58) 56% 18%
Posaconazole 1.08 (0.53–2.21) 46% 23%
Voriconazole 0.63 (0.35–1.09) 73% 49%
IFI, invasive fungal infections; IA, invasive aspergillosis; IC, invasive candidiasis; OLAT, other licensed antifungal therapy.
aEstimates less than zero indicate a reduced probability of proven/probable IFI at 180 days relative to fluconazole.
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report the probabilities of outperforming fluconazole
or of being the best agent overall for each mould-
active azole, which physicians can then factor into the
selection process [38].
While our base-case MTC analysis allowed for sub-
stantial heterogeneity across the studies, our conserva-
tive approach came at the cost of a reduced statistical
inference and wider credible intervals, thereby reducing
our ability to detect actual differences between treatments.
Thus, the available data did not allow our base-case MTC
to distinguish between itraconazole, posaconazole, and
voriconazole when using the 5% threshold for type-I error
typically employed in classical hypothesis testing. Our
sensitivity analysis using an empirical prior yielded
some comparisons that did meet the traditional 5%
threshold, ie, itraconazole and voriconazole had lower
IFI risk and posaconazole and voriconazole had lowerIA risk than fluconazole. Regardless, our objective was
not to test causal research hypotheses (when prespeci-
fied confidence thresholds are useful), but rather to help
decision-makers compare the efficacy of different inter-
ventions [39,40].
Although regulatory authorities will always prefer a
high degree of certainty for these comparisons, the
requirement for a specific threshold of “confidence”
(typically 95%) may result in sub-optimal outcomes in
situations where a treatment decision cannot be deferred
[41,42]. Such is the case for antifungal prophylaxis in
alloHCT recipients: while the most efficacious oral agent
is currently unknown, a choice must still be made in
those patients who are deemed to benefit from a
prophylactic approach. The probabilities of superiority
estimated by MTC represent an objective measure of
comparative efficacy that can be taken into account
when making this choice.
Table 3 Estimated treatment effect for each outcome relative to fluconazole (sensitivity analysis using an empirical
prior)
Comparator Median posterior odds-ratio relative
to fluconazole (interquartile range)a
Posterior probability of having
lower incidence than fluconazole
Posterior probability of having the
lowest incidence of all treatments
Proven/probable IFI at 180 days
Fluconazole – – 0%
Itraconazole 0.54 (0.42–0.67) 95% 27%
Posaconazole 0.57 (0.41–0.76) 88% 29%
Voriconazole 0.47 (0.36–0.63) 95% 44%
Proven/probable IA at 180 days
Fluconazole – – 0%
Itraconazole 0.68 (0.53–0.90) 82% 4%
Posaconazole 0.30 (0.20–0.45) 96% 59%
Voriconazole 0.37 (0.26–0.54) 96% 36%
Proven IC at 180 days
Fluconazole – – 2%
Itraconazole 0.31 (0.19–0.49) 95% 71%
Posaconazole 0.97 (0.49–1.96) 51% 16%
Voriconazole 0.90 (0.49–1.69) 55% 12%
All-cause mortality
Fluconazole – – 22%
Itraconazole 1.18 (1.03–1.34) 21% 7%
Posaconazole 0.98 (0.82–1.16) 54% 41%
Voriconazole 1.01 (0.88–1.17) 48% 30%
OLAT use at 180 days
Fluconazole – – 3%
Itraconazole 0.95 (0.78–1.14) 58% 7%
Posaconazole 1.07 (0.83–1.37) 43% 12%
Voriconazole 0.64 (0.54–0.75) 94% 79%
IFI, invasive fungal infections; IA, invasive aspergillosis; IC, invasive candidiasis; OLAT, other licensed antifungal therapy.
aEstimates less than zero indicate a reduced probability of proven/probable IFI at 180 days relative to fluconazole.
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analysis did achieve statistical significance at the standard
95% level in several of the important outcomes: the pos-
terior probabilities of itraconazole/voriconazole being
superior to fluconazole for prevention of IFI overall,
posaconazole/voriconazole being better than flucona-
zole for prevention of IA, and itraconazole being better
than fluconazole for prevention of IC. The probability
of voriconazole being superior to fluconazole for the
reduction of OLAT use was found to be 94% in this
sensitivity analysis. Empirical Bayesian methods are some-
times criticized for “using the data twice” [43], which is
the reason this approach was not chosen for the base-case
analysis. However, this method can improve statistical in-
ference and has previously been shown to provide accur-
ate inference in random effects meta-analysis [24].
Based on estimated probabilities of superiority, our ana-
lyses suggest that broad-spectrum mould-active azoles aremore effective than fluconazole as antifungal prophylaxis
in alloHCT recipients post-transplant, a result largely
driven by fluconazole’s lack of anti-mould activity; this
finding is consistent with a previously published meta-
analysis [8]. Among the mould-active azoles, posaconazole
and voriconazole reduced the risk of IA more than itraco-
nazole. In contrast, itraconazole was the most effective in
preventing IC, which is also consistent with published
meta-analyses [20,44]. Compared with fluconazole, vorico-
nazole had the greatest probability of reducing OLAT use,
which may have both clinical and pharmacoeconomic im-
plications. Other outcomes of potential interest, such as
incidence of possible IFI and fungal-free survival, could
not be evaluated, since relevant data were not consistently
reported in the eligible RCTs.
Currently, IFI caused by Aspergillus spp. predominate
[2,3] and reduced intensity conditioning (RIC) trans-
plants are now commonplace, with 42% of patients in
Figure 3 Treatment effect of antifungal agents on A) proven/probable invasive fungal infection (IFI) and B) proven/probable invasive
aspergillosis (IA) at 180 days, compared between the base-case mixed treatment comparison (MTC) and the sensitivity analysis MTC
using an empirical prior, expressed in log odds. Estimates less than zero indicate a reduced probability of IFI relative to fluconazole. The
vertical bar of the box plot represents the posterior median value (probability <50%); the outer limits of the box plot represent the posterior
interquartile range (probability 25%–75%); whiskers represent the most extreme Markov Chain Monte Carlo values of the posterior no more than
1.5 times the width of the interquartile range above or below the upper or lower bounds of the interquartile range.
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undergone RIC/nonmyeloablative conditioning [10]. In
RIC patients, IFIs, particularly invasive mould infections,
tend to occur during the late post-engraftment period
(ie, after day 100) [2,45]; these patients may therefore re-
quire longer periods of mould-active antifungal prophy-
laxis. Of note, the studies included into our evidence
network assessed patients for a post-engraftment period
of up to 180 days, but the at-risk period for invasive
mould infections extends beyond this period [2,3,45].
The included studies were heterogeneous in terms of the
study design, patient population and risk of IFI, such that
recognition of possible treatment effects may have been
obscured. For example, the IFI rates varied across the
studies and are likely to reflect a similar variance in IFI risk.
The highest IFI rate was observed in the study by Winston
and colleagues [29] where a greater proportion of flucona-
zole recipients received unrelated donor stem cells, and
had a higher incidence of acute and chronic graft-versus-
host disease (GvHD), thus amplifying the difference in IFI
event rates between study and control groups.
The incidence of grades II–IV acute GvHD as a risk fac-
tor for IFI also varied significantly among the studies from
100% [27], to 64% [26], 46% [10], 41% [28], and 37% [29].
The IFI risk may have been influenced by the heterogen-
eity of conditioning regimen intensities among the studies
included in the analysis.All (100%) subjects in the Seattle study [26] and the
study of Blood and Marrow Clinical Trials Network [28]
received myeloablative conditioning regimens compared
to 78% in the study by Winston et al. [29] and 58% in
the multicentre European study [10]. Accordingly, the
influence of pre-engraftment myelosuppression and cyto-
toxic therapy-induced intestinal epithelial damage on IFI
risk may have varied among the studies.
There was a significant variance in the prophylaxis
start dates among the studies ranging from the beginning
of conditioning [26], to the day of transplant [10,28], the
day after transplant [29], and the day of documentation of
GvHD (median of day 64 post-transplant) [27]. This latter
study only reported IFI incidence at 112 days post-
treatment initiation, and did not address the incidence of
IFI and OLAT use between the time of transplant and the
start of study prophylaxis [27]. The decision to include the
posaconazole trial was validated by the alignment of the
results of the base-case analysis with those of the post-hoc
sensitivity analysis in which the study was excluded.
Similarly, there were significant variations in toxicity-
or intolerance-driven drug withdrawal rates that likely
influenced prophylaxis drug exposure and efficacy. Itra-
conazole withdrawal rates ranged from a low of 8.5%
[29], to 36% [26] and 43% [10]. Fluconazole withdrawal
rates ranged from 1.5% [29], to 16% [26], 38% [27], and
44% [28]. Voriconazole withdrawal rates were similar at
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rate was 34% [27]. Our inability to control for all of
these different variables, reflected in the heterogeneity of
the included studies, reduced the sensitivity of the ana-
lysis to detect treatment effects for the outcome of inter-
est, the use of a random effects model notwithstanding.
Application of the 2008 revised definitions for the
end-points for the prophylaxis studies [46] may have
provided a more robust basis for prophylaxis efficacy
outcomes as has been noted for treatment outcomes
[47,48]; however, we used the definitions for invasive
fungal infection employed in the methods of the in-
cluded trials for consistency.
Comparative efficacy notwithstanding, considerations
that may impact the decision-making process include cost
differences, ease of use, availability of an intravenous for-
mulation (in case of mucositis and/or intestinal GvHD),
adverse event and drug-drug interaction profile, availabil-
ity of expertise and diagnostic tools for early diagnosis of
invasive mould infection, and local IFI epidemiology.
While substantial cost differences exist between generic
fluconazole and itraconazole on the one hand and posaco-
nazole and voriconazole on the other, the drug costs asso-
ciated with OLAT should be considered as well. Oral and
gastrointestinal mucositis may limit the role of posacona-
zole due to the unavailability of an intravenous formula-
tion and the requirement for administration with a full
meal [49]. Of note, all of the mould-active azoles adversely
interact with immunomodulatory and antineoplastic
drugs. Prophylactic fluconazole may be a worthwhile alter-
native to mould-active prophylaxis in alloHCT in centres
practicing early diagnostics-driven therapy [8].
It should be noted that patient-level data (from published
papers), rather than (raw) data extracted from clinical study
reports, were used to drive this MTC meta-analysis.
Conclusions
We cannot firmly conclude that specific agents per-
formed better than others in any of the evaluated out-
comes, due to the width of credible intervals in the
base-case analysis. However, from a medical decision-
making point of view, the results support the selection
of mould-active azoles over fluconazole for the preven-
tion of IFIs in alloHCT recipients post-transplant. In
addition, posaconazole and voriconazole may be prefer-
able for protection from IA, itraconazole for protection
from IC, and voriconazole for reducing OLAT use,
based on the respective relatively high posterior prob-
abilities (which were nevertheless <95% in most cases).
In order to more conclusively assess comparative
efficacy, future research in the form of additional
(multi-arm) RCTs is likely to be necessary. Given the
current paucity of comparative data between the mould-
active azoles, other considerations such as availability ofan intravenous formulation, local IFI epidemiology,
and drug costs, may be factors to consider when
choosing between these agents.
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